Medical Devices

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

With a new flexible, founder-first model, Activation Capital's Frontier BioHealth program aims to bridge the commercialization gap for life sciences startups.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

Peijia Medical submits its innovative GeminiOne heart valve repair system for EU approval, signaling a new challenge to established players in the market.

Johnson & Johnson unveils promising data for its next-gen AFib tech while reinforcing the safety of its current platform in a competitive market.

Hemex Health's portable Gazelle test gets FDA Breakthrough status, paving an accelerated path for a device already changing lives in over 40 countries.

A vague error code on millions of TRUE METRIX glucose meters led to delayed care. The company is now issuing a critical warning to prevent further harm.

A national scholarship founded by a top neurosurgeon invests in students poised to solve healthcare’s biggest challenges, addressing critical workforce shortages.

The medical device giant posts 6% Q1 growth but faces major challenges from US reimbursement changes and a China recall, banking on a new acquisition.

South Korean firm Neurophet wins its third FDA clearance for an AI tool that precisely tracks Alzheimer's therapy side effects, eyeing U.S. expansion.

Australian biotech Immutep reaches a key milestone in its Phase III trial for a novel lung cancer therapy, a major step in a multi-billion dollar market.

With rapid trial enrollment for a novel drug, Pulmovant offers a potential lifeline for patients with PH-ILD, a condition with few to no options.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Ascentage Pharma's next-gen BTK degrader, APG-3288, receives dual IND clearance, paving the way for clinical trials to fight resistant blood cancers.

Hawk Ridge Systems expands its portfolio with Stratasys' production-grade 3D printing, aiming to dominate the end-to-end additive manufacturing market.

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.